ATE262338T1 - Verwendung von bisphosphonaten zur behandlung der vaskulären restenose - Google Patents

Verwendung von bisphosphonaten zur behandlung der vaskulären restenose

Info

Publication number
ATE262338T1
ATE262338T1 AT99929687T AT99929687T ATE262338T1 AT E262338 T1 ATE262338 T1 AT E262338T1 AT 99929687 T AT99929687 T AT 99929687T AT 99929687 T AT99929687 T AT 99929687T AT E262338 T1 ATE262338 T1 AT E262338T1
Authority
AT
Austria
Prior art keywords
bisphosphonates
vascular restenosis
treat vascular
treat
restenosis
Prior art date
Application number
AT99929687T
Other languages
English (en)
Inventor
Gershon Golomb
Haim Daneberg
Jukka Monkkonen
Ilia Fishbein
Original Assignee
Yissum Res Dev Co
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Hadasit Med Res Service filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE262338T1 publication Critical patent/ATE262338T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT99929687T 1998-07-14 1999-07-14 Verwendung von bisphosphonaten zur behandlung der vaskulären restenose ATE262338T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12533698A IL125336A0 (en) 1998-07-14 1998-07-14 Compositions for inhibition and treatment of restinosis
PCT/IL1999/000387 WO2000003677A2 (en) 1998-07-14 1999-07-14 Use of bisphosphonates in the treatment of vascular restenosis

Publications (1)

Publication Number Publication Date
ATE262338T1 true ATE262338T1 (de) 2004-04-15

Family

ID=11071743

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99929687T ATE262338T1 (de) 1998-07-14 1999-07-14 Verwendung von bisphosphonaten zur behandlung der vaskulären restenose
AT04006854T ATE471149T1 (de) 1998-07-14 1999-07-14 Verwendung von bisphosphonaten zur behandlung von vaskulärer restenose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04006854T ATE471149T1 (de) 1998-07-14 1999-07-14 Verwendung von bisphosphonaten zur behandlung von vaskulärer restenose

Country Status (17)

Country Link
US (1) US6719998B1 (de)
EP (2) EP1468691B1 (de)
JP (4) JP4663116B2 (de)
KR (1) KR20010074711A (de)
CN (1) CN1321090A (de)
AT (2) ATE262338T1 (de)
AU (1) AU758882B2 (de)
BR (1) BR9912066A (de)
CA (1) CA2337175C (de)
DE (2) DE69915834T2 (de)
EE (1) EE200100025A (de)
ES (2) ES2219028T3 (de)
IL (3) IL125336A0 (de)
NO (1) NO20010224L (de)
PL (1) PL345782A1 (de)
SK (1) SK472001A3 (de)
WO (1) WO2000003677A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
EP1267888A4 (de) * 2000-01-04 2005-12-28 Univ California Verwendung von niedrigdosierten bisphosphonaten zur verhinderung der verkalkung von herz und arterien
EP1372753B1 (de) * 2001-02-16 2007-08-01 Abbott Laboratories Vascular Enterprises Limited Implantate mit fk506 zur restenosebehandlung und -prophylaxe
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
JP2006504749A (ja) * 2002-10-15 2006-02-09 ノバルティス アクチエンゲゼルシャフト アテローム性動脈硬化症の処置のためのビスホスホネートおよびそれらを含むデバイス
US8034361B2 (en) * 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
WO2005002545A1 (en) * 2003-06-27 2005-01-13 Biorest Ltd. Method of treating acute coronary syndromes
US20050153937A1 (en) * 2003-11-07 2005-07-14 Gershon Golomb Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
US7687482B2 (en) 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006087722A1 (en) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8802184B2 (en) 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
US20090099651A1 (en) * 2007-10-10 2009-04-16 Miv Therapeutics, Inc. Lipid coatings for implantable medical devices
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
EP2255199A1 (de) * 2008-02-19 2010-12-01 Jovesis Inc. Mikropartikelzusammensetzungen zur modifikation krebsfördernder zellen
BRPI0915885A2 (pt) * 2008-07-09 2015-11-03 Univ Nebraska micelas funcionais para a liberação direcionada de substâncias químicas em tecido duro
US20130315981A1 (en) * 2010-06-25 2013-11-28 The Trustees Of Columbia University In The City Of New York Method for inducing fat loss in mammals
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP2769741A1 (de) * 2013-02-22 2014-08-27 Cardiatis S.A. Medizinische Vorrichtung mit biokompatibler Beschichtung
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
AU2015258964B2 (en) 2014-05-16 2018-01-04 Oregon Health And Science University Use of bisphosphonates as HIV/AIDS adjunctive treatment
JP6910033B2 (ja) * 2016-08-01 2021-07-28 株式会社カネカ カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
CN106361701B (zh) * 2016-08-31 2019-08-27 上海交通大学 一种脂质体药物载体及其制备方法和应用
FR3068233A1 (fr) * 2017-07-03 2019-01-04 Omnium De Revalorisation Industrielle Odri Dispositif medical intra-arteriel et applications
JP6613290B2 (ja) 2017-11-28 2019-11-27 株式会社Ｓｕｂａｒｕ 運転アドバイス装置及び運転アドバイス方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
WO1988000289A1 (en) 1986-07-09 1988-01-14 Engine Technology Limited Piston rings
CH675422A5 (de) * 1988-03-31 1990-09-28 Symphar Sa
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
CA2042159A1 (en) 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2124857A1 (en) * 1991-11-11 1993-05-27 Howard C. Herrmann Methods of inhibiting restenosis
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5652227A (en) 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
WO1997043437A2 (en) * 1996-05-15 1997-11-20 The University Of Sheffield Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
JP2001509176A (ja) * 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5760030A (en) 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
AU760703B2 (en) * 1998-01-29 2003-05-22 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US5932563A (en) 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
EP1135397B1 (de) 1998-12-10 2003-04-23 Aesgen, Inc. Verfahren zur herstellung von dinatriumpamidronat
EP1210138A4 (de) 1999-04-22 2003-05-07 Hydro Med Sciences Inc Kontrollierte verabreichung von bisphosphonaten

Also Published As

Publication number Publication date
JP4663116B2 (ja) 2011-03-30
US6719998B1 (en) 2004-04-13
JP2011037871A (ja) 2011-02-24
JP2016041724A (ja) 2016-03-31
DE69942510D1 (de) 2010-07-29
JP5498342B2 (ja) 2014-05-21
IL142172A (en) 2007-07-24
EP1094820A2 (de) 2001-05-02
KR20010074711A (ko) 2001-08-09
CA2337175C (en) 2009-03-31
NO20010224D0 (no) 2001-01-12
NO20010224L (no) 2001-03-09
JP5903081B2 (ja) 2016-04-13
EP1468691A1 (de) 2004-10-20
EE200100025A (et) 2002-06-17
PL345782A1 (en) 2002-01-02
EP1468691B1 (de) 2010-06-16
AU758882B2 (en) 2003-04-03
ATE471149T1 (de) 2010-07-15
CA2337175A1 (en) 2000-01-27
SK472001A3 (en) 2001-09-11
EP1094820B1 (de) 2004-03-24
DE69915834T2 (de) 2005-03-24
AU4646299A (en) 2000-02-07
JP2002520345A (ja) 2002-07-09
JP6088619B2 (ja) 2017-03-01
DE69915834D1 (de) 2004-04-29
BR9912066A (pt) 2001-04-10
WO2000003677A2 (en) 2000-01-27
WO2000003677A3 (en) 2000-05-04
IL142172A0 (en) 2002-03-10
IL125336A0 (en) 1999-03-12
JP2013256524A (ja) 2013-12-26
ES2347553T3 (es) 2010-11-02
CN1321090A (zh) 2001-11-07
ES2219028T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
ATE262338T1 (de) Verwendung von bisphosphonaten zur behandlung der vaskulären restenose
DE69310065D1 (de) Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
DE69218624D1 (de) Behandlung von peridontalkrankheiten mit alendronat
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69427344D1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
ATE293450T1 (de) Verwendung von biphosphonsäuren zur behandlung von angiogenese
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
BR9807883A (pt) Compostos de tetraidropirido
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
ATE156359T1 (de) Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis
ATE238315T1 (de) Verfahren zur herstellung von dinatriumpamidronat
DE59908511D1 (de) Verfahren zur peroxidischen Behandlung von Olefinpolymerisaten
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE263566T1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
ATE273013T1 (de) Verwendung von simethicone zur behandlung der ulzerativen kolitis
DE69214647D1 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
ATE263556T1 (de) Phenylessigsäure enthaltende zusammensetzungen zur behandlung und vorbeugung der atherosklerose und der restenose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties